IOL Chemicals and Pharmaceuticals Limited (524164) Earnings Call Transcripts

IOL Chemicals and Pharmaceuticals Limited's Latest Earnings Call - Q4 FY2026

In Q4 FY '26, IOL Chemicals and Pharmaceuticals Limited reported a strong performance with revenue from operations reaching INR 619 crores, reflecting a year-on-year growth of 17.4%. The company achieved a profit after tax (PAT) of INR 53 crores, up 68% from the previous year, driven by improved operational efficiencies and capacity utilization. Management maintained guidance for FY '27, projecting mid-teen revenue growth and EBITDA margins of 14% to 15%. This robust performance and positive outlook could enhance investor confidence and potentially move the stock positively.

Reported metrics

Guidance from management

Management expects mid-teen revenue growth and EBITDA margins of 14% to 15% for FY '27, maintaining their previous guidance amidst positive operational trends.

What management said

So I think we are still maintaining that. The improvement I think quantity, actually, when we've given that improvement this year we set the 27 by 27%, so we are very sure about that we will be achieving it. But I think we will be remaining to that level, perhaps maybe a little bit improved. But semi side on a conservative side, we are if we say 27% by 27% from this. So I think it's around mid- to high-teen growth nu...

There is as we have mentioned earlier that the demand is not in every product, but in special in due around 3, 4 quarters ago, the demand was lower due to restocking of productive do refi '23, '24, year '23 and '24. But for and the entrance of a new peer also in the market. But we were expecting that demand will be stabilized after destocking at these levels. And we were expecting these demand especially do from Octo...

What analysts pressed on

Analysts expressed concerns about the sustainability of margin improvements given rising raw material costs and the competitive landscape in the pharmaceutical sector. There were questions regarding the impact of global supply chain issues on future performance.

Main topics on the call

• Revenue Growth — The company reported revenue of INR 619 crores for Q4 FY '26, a 17.4% increase year-on-year, attributed to 'cost optimization, improving product mix and enhanced capacity utilization'. Management expressed confidence in ...
• Profitability Improvement — Q4 FY '26 saw a PAT of INR 53 crores, a 68% increase from the previous year, with a PAT margin improvement to 8.6%. Management indicated that this was supported by 'improved operating profitability and efficient working ...
• Capacity Utilization — The company achieved high capacity utilization rates, with '85% to 95% capacity utilized' across key products. This operational efficiency is expected to continue contributing to revenue growth.
• Future Guidance — Management maintained guidance for FY '27, projecting 'mid-teens to high-teens revenue growth' and EBITDA margins of '14% to 15%'. This reflects confidence in ongoing operational improvements and market demand.

Read the full IOL Chemicals and Pharmaceuticals Limited transcript (Q4 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 12 IOL Chemicals and Pharmaceuticals Limited earnings call transcripts on record, spanning November 15, 2022 to May 22, 2026. Based on this history, IOL Chemicals and Pharmaceuticals Limited reports semi-annually. The most recent call on file is dated May 22, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

524164

Exchange

BSE

Country

IN

Sector

Health Care

Industry

Pharmaceuticals

Calls on record

12

First call

November 15, 2022

Most recent

May 22, 2026

Reporting cadence

semi-annually